Camrelizumab/LenvatinibCerebral haemorrhage and immune-related pneumonia: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2038卷 / 1期

关键词：

D O I：

10.1007/s40278-024-72179-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：70 / 70

相关论文

共 50 条

[21] Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab
Zhang, Chuantao
Wang, Guanqun
Liu, Ning
Li, Tianjun
Zhu, Jingjuan
Hou, Helei
FRONTIERS IN IMMUNOLOGY, 2024, 15
[22] Multiple drugsLack of effiacacy, cardiogenic shock and immune-related myocarditis: 2 case reports
Reactions Weekly, 2024, 2031 (1) : 254 - 254
[23] Camrelizumab/doxorubicin/pembrolizumabImmune-related pneumonitis: 2 case reports
Reactions Weekly, 2020, 1798 (1) : 70 - 70
[24] Camrelizumab/sintilimabColitis: 2 case reports
Reactions Weekly, 2023, 1950 (1) : 104 - 104
[25] BlinatumomabCytokine release syndrome and immune-related pneumonia syndrome: case report
Reactions Weekly, 2021, 1858 (1) : 85 - 85
[26] Camrelizumab/sintilimabHypophysitis: 2 case reports
Reactions Weekly, 2023, 1961 (1) : 107 - 107
[27] Multiple drugsGastrointestinal immune-related adverse events: 5 case reports
Reactions Weekly, 2019, 1771 (1) : 211 - 212
[28] Ipilimumab/nivolumabColitis, hepatotoxicity and immune-related encephalitis: 3 case reports
Reactions Weekly, 2021, 1853 (1) : 256 - 256
[29] Nivolumab/pembrolizumabNeurological immune-related adverse events: 4 case reports
Reactions Weekly, 2023, 1977 (1) : 235 - 235
[30] Monoclonal antibodiesRheumatic immune-related adverse events: 11 case reports
Reactions Weekly, 2018, 1726 (1) : 239 - 239

← 1 2 3 4 5 →